• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Clene Inc. - Common Stock (NQ:CLNN)

    5.770 -0.520 (-8.27%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Clene Inc. - Common Stock

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Lead Drug Candidate Featured in Peer-Reviewed Publication Describing Brain Target Engagement in Neurodegenerative Diseases
    Via Investor Brand Network
    Stem Cell Therapy Shows Promise in Halting Progression of Cognitive Decline in MS Patients
    Via Investor Brand Network
    BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’
    Via Investor Brand Network
    News headline image
    Expert Ratings for Clene ↗
     
    Via Benzinga
    The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles
    Via Investor Brand Network
    Study Suggests Parkinson’s Could Be Linked to Onset of Stroke, Heart Disease
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) Capitalizing on the Promising Chemical and Therapeutic Properties of Nanocrystals to Address High Unmet Medical Needs
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program
    Via Investor Brand Network
    Blood Test Could Detect Worsening MS Symptoms in Patients
    Via Investor Brand Network
    News headline image
    Where Clene Stands With Analysts ↗
     
    Via Benzinga
    Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS
    Via Investor Brand Network
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights
    Via Investor Brand Network
    Australian Study Finds Way to Detect Parkinson’s Prior to Symptom Onset
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study
    Via Investor Brand Network
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS
    Via Investor Brand Network
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology
    Via Investor Brand Network
    Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS
    Via Investor Brand Network
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast
    Via Investor Brand Network
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
     
    Via Benzinga
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS
    Via Investor Brand Network
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal
    Via Investor Brand Network
    News headline image
    Clene's Neurogenerative Candidate Shows Potential For Improved Long-Term Survival ↗
    Clene Inc. (NASDAQ: CLNN) released long-term follow-up data for patients treated with CNM-Au8 30mg for up to 133 weeks in the  
    Via Benzinga
    InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Significant Long-Term Survival Improvement Data from ALS Trial
    Via Investor Brand Network
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Clene And 2 Other Stocks Under $3 Insiders Are Aggressively Buying ↗
    The Dow Jones closed higher by over 200 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
    Via Benzinga
    BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $40M Public Offering
    Via Investor Brand Network
    News headline image
    Uber To Rally Around 55%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
    Rosenblatt boosted the price target for Lumentum Holdings Inc. (NASDAQ: LITE) from $48 to $67. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Lumentum shares fell 1.3% to $60.56 in... 
    Via Benzinga
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.